Abstract
N-acetylcysteine (NAC), the N-acetyl derivative of the amino acid cysteine, is perhaps best known for its wide use in the treatment of acetaminophen (paracetamol) toxicity, but it has been investigated for the treatment of myriad conditions. In this article we will review the uses of NAC in pulmonary diseases, the mechanism of action dosing, side effect profile and clinical implications in regard to COPD and idiopathic pulmonary fibrosis. One of the main targets of NAC is Inflammation and oxidative stress that are important factors in the pathogenesis of many chronic inflammatory lung disorders. While it is logical to conclude that the administration of antioxidants such as NAC will provide a mode of treatment for said conditions by targeting antioxidant-oxidant imbalance [8] and although the theory supporting the use of antioxidants is sound, it may not necessarily translate into clinical benefit. Based on the available evidence it is unlikely that mucolytics such as NAC will drastically affect symptoms, exacerbations or disease modification in COPD.
Keywords: Interstitial lung diseases, N-Acetylcysteine, pulmonary diseases, side effects.
Current Respiratory Medicine Reviews
Title:The Use of N-Acetylcysteine in Respiratory Diseases
Volume: 9 Issue: 5
Author(s): Shoshannah Levitt, Daniel Grupel, Maor Waldman, Tamir Tobias and Theodore K. Marras
Affiliation:
Keywords: Interstitial lung diseases, N-Acetylcysteine, pulmonary diseases, side effects.
Abstract: N-acetylcysteine (NAC), the N-acetyl derivative of the amino acid cysteine, is perhaps best known for its wide use in the treatment of acetaminophen (paracetamol) toxicity, but it has been investigated for the treatment of myriad conditions. In this article we will review the uses of NAC in pulmonary diseases, the mechanism of action dosing, side effect profile and clinical implications in regard to COPD and idiopathic pulmonary fibrosis. One of the main targets of NAC is Inflammation and oxidative stress that are important factors in the pathogenesis of many chronic inflammatory lung disorders. While it is logical to conclude that the administration of antioxidants such as NAC will provide a mode of treatment for said conditions by targeting antioxidant-oxidant imbalance [8] and although the theory supporting the use of antioxidants is sound, it may not necessarily translate into clinical benefit. Based on the available evidence it is unlikely that mucolytics such as NAC will drastically affect symptoms, exacerbations or disease modification in COPD.
Export Options
About this article
Cite this article as:
Levitt Shoshannah, Grupel Daniel, Waldman Maor, Tobias Tamir and Marras K. Theodore, The Use of N-Acetylcysteine in Respiratory Diseases, Current Respiratory Medicine Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/1573398X10666140204230324
DOI https://dx.doi.org/10.2174/1573398X10666140204230324 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Characteristics of Asian Mosquito Saliva Allergens for Specific Diagnoses and Effective Therapies
Current Protein & Peptide Science Genes and Hypertension
Current Pharmaceutical Design Prevalence of Intestinal Parasites among Patients with Chronic Urticaria in Northern Iran
Infectious Disorders - Drug Targets Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Allergy After Inhalation and Ingestion of Cereals Involve Different Allergens in Allergic and Celiac Disease
Recent Patents on Inflammation & Allergy Drug Discovery Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery Peptides As Therapeutics with Enhanced Bioactivity
Current Medicinal Chemistry Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Chronic Spontaneous Urticaria: Epidemiological Characteristics Focusing on the Histocompatibility Profile and Presence of Antibodies
Inflammation & Allergy - Drug Targets (Discontinued) Occupational Allergy in Healthcare Workers
Recent Patents on Inflammation & Allergy Drug Discovery Isolated Unilateral Tongue Oedema: The Adverse Effect of Angiotensin Converting Enzyme Inhibitors
Current Drug Safety Histamine-Dependent and -Independent Hypersensitivity Reactions to Contrast Media: The Impact of Antihistamines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adenovirus Vectors and Subviral Particles for Protein and Peptide Delivery
Current Gene Therapy Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach
Current Vascular Pharmacology Adverse Effects of Antihistamines on Skin Tests and Antihistamines in Pregnancy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design